Cancer Biomarkers Market

Cancer Biomarkers Market

Cancer Biomarkers Market Forecasts to 2028 - Global Analysis By Cancer Type (Melanoma, Bladder Cancer and Other Cancer Types), Product (Software, Consumables and Other Products), Profiling Technologies (Immunoassay, Omics Technologies and Other Profiling Technologies), Application (Prognostics, Diagnostics and Other Applications), Biomarkers Type, Service and By Geography

4.4 (59 reviews)
4.4 (59 reviews)
Published: 2023 ID: SMRC23057

This report covers the impact of COVID-19 on this global market

Years Covered


Estimated Year Value (2022)

US $14.70 BN

Projected Year Value (2028)

US $40.92 BN

CAGR (2022 - 2028)


Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

Asia Pacific

Highest Growing Market


According to Stratistics MRC, the Global Cancer Biomarkers Market is accounted for $14.70 billion in 2022 and is expected to reach $40.92 billion by 2028 growing at a CAGR of 18.6% during the forecast period. In oncology, biomarkers are substances that a tumour or a particular human body reaction secretes to indicate the presence of malignancy. Using diverse genomes and proteomics methods, biomarkers enable early cancer detection and quick, noninvasive diagnosis of the disease. Applications for biomarkers include prognostics, personalised medicine, drug research and development, and cancer diagnosis.

According to, the National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer was diagnosed in the United States. According to the World Cancer Research Fund International, an estimated 18.0 million people were suffering from globally in 2018. Lung and breast cancers were the most common cancers reported globally, contributing to 12.3% of the total number of the cases diagnosed in 2018.

Market Dynamics:


Rising prevalence of cancer

Cancer biomarkers are widely utilised in personalised medicine, companion diagnostics, and other disease diagnostics, including risk assessment for disease and drug development. One of the primary factors anticipated to propel the growth of the cancer biomarkers market during the forecast period is the increasing utilisation of biomarkers in disease diagnosis. Globally increasing rates of cancer are driving up demand for early disease detection and, in turn, driving the market's expansion. The demand for cancer diagnostics and treatment is expected to raise as the prevalence of cancer biomarkers increases in both emerging and developed nations.


High treatment cost

An international issue that jeopardises patient access to care and the effectiveness of cancer therapy is the rising price of cancer medications. The cost of drugs varies widely between different countries. In nations without universal health coverage, patients must pay for their medical care. Most patients in low- and middle-income countries cannot afford novel cancer therapies. The most serious risks are to younger patients, new immigrants, people of colour, and those without private health insurance. Value-based oncology treatment pricing can promote the creation of better therapeutics and cut down on unnecessary spending.


Presence of potential pipeline candidates

The pharmaceutical sector has made a large investment in the search for novel biomarkers that can be used to monitor and identify cancer. Several contenders' development cycles are coming to a close. This is expected to significantly increase market growth. For instance, Lund University Hospital is working with the South Sweden Breast Cancer Group to undertake clinical trials comparing the efficiency and safety of atorvastatin. The creation of new biomarkers for the early diagnosis of cancer should be advantageous for the oncology biomarker sector. Due to the growing availability of cancer biomarker-related goods and diagnostics, the market is anticipated to expand.


Lack of reimbursement policies for biomarker testing

The lack of reimbursement policies for biomarker testing in emerging and developed nations is one of the factors that is restricting the demand for these biomarkers globally, despite the rising prevalence of cancer around the world and the growing number of patients needing diagnostic tests. The high cost of cancer diagnosis and treatment in developing nations is another significant issue limiting the market's growth. Due to this, fewer patients are having biomarker testing, and more patients are favouring other inexpensive detection methods.

Covid-19 Impact

The COVID-19 pandemic had a negative impact on the cancer biomarkers market, owing to the interrupted research and development activities during this period. Additionally, the SARS-CoV-2 infection can produce biomarker data that are difficult to interpret. For instance, according to information supplied by the Society for Endocrinology in September 2020, indicators of the immunological response to cancer may be difficult to interpret due to the potential confounding effect of the strong immune response to acute viral infection. In addition, the U.K. delayed normal cancer screening as a result of the COVID-19 pandemic, according to a National Centre for Biotechnology Information report.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is estimated to have a lucrative growth. A huge patient pool undergoing diagnostic testing is a result of the rising incidence of breast cancer and increased awareness of the diagnosis of the disease. Some of the key reasons influencing the growth of the breast cancer segment include this along with an increase in research activities concentrating on new biomarkers for breast cancer detection.

The diagnostics segment is expected to have the highest CAGR during the forecast period

The diagnostics segment is anticipated to witness the fastest CAGR growth during the forecast period, due to advancements in cancer detection and therapy, the emphasis has switched from immediate objectives like curing the disease to longer-term objectives like improving the quality of life for cancer survivors, particularly those with paediatric tumours. It is anticipated that the growing acceptance of companion diagnostic tests for cancer treatments will bolster market growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the high number of cancer cases in the region. Rising public awareness of the need of early cancer detection is one of the primary factors propelling the market's revenue growth in this area. Additionally, a significant population base in the area contributes to the market's revenue growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. There has been the identification of a critical biomarker for estimating cancer risk and early cancer detection. A quantitative method to determine when someone is likely to develop cancer is provided by biomarkers, especially those linked to hereditary factors. The growing demand for cancer diagnostics, which is powered by the rising incidence rates of different malignancies, is what is driving market expansion in this region.

Key players in the market

Some of the key players profiled in the Cancer Biomarkers Market include Abbott Laboratories, Myriad Genetics, Inc., F. Hoffmann-LA Roche Ltd., Asuragen, Inc., Biomérieux SA, Seegene Technologies, INC., Thermo Fisher Scientific INC., R&d Systems, Inc., Becton Dickinson and Company, Qiagen N.V., Hologic, Inc., Illumina, Inc., Bio-Rad Laboratories, INC., Agilent Technologies and Merck Millipore.

Key Developments:

In March 2021, Roche made an announcement that company has received the approval from US Food and Drug Administration for VENTANA ALK (D5F3) CDx Assay as a companion diagnostic. This assay test is the only test which was approved by FDA for as a companion diagnostic for LORBRENA and will help in identifying patients with this cancer biomarker quickly so they can be given more effective treatment.

In November 2020, Agilent Technologies Inc. made an announcement of the launch of the Biomarker Pathologist Training Program which is a worldwide initiative built to enable pathologists to score biomarkers precisely. The program initially was available in Europe and North America, along with China and Asia which utilizes a digital platform.

In July 2020, Thermo Fisher Scientific has announced that the company has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., and has applied to the Ministry of Health, Labour and Welfare (MHLW) to increase the use of the Oncomine Dx Target Test in Japan. This agreement focuses on accelerating the local biomarker testing of NSCLC patients eligible for entrectinib in Japan.

Cancer Types Covered:
• Melanoma
• Bladder Cancer
• Breast Cancer
• Kidney Cancer
• Prostate Cancer
• Lung Cancer
• Non-Hodgkin's Lymphoma
• Colorectal Cancer
• Thyroid Cancer
• Leukemia
• Other Cancer Types

Products Covered:
• Software
• Consumables
• Growth Hormone Therapy
• Services
• Other Products

Profiling Technologies Covered:
• Immunoassay
• Omics Technologies
• Cytogenetics
• Imaging Technologies
• Bioinformatics
• Other Profiling Technologies

Applications Covered:
• Prognostics
• Diagnostics
• Risk Assessment
• Research & Development
• Hospitals & Specialty Clinics
• Pharmaceutical & Biotechnology Companies
• Other Applications

Biomarkers Types Covered:
• Genetic Biomarkers
• Protein Biomarkers
• Safety
• Pharmacodynamics
• Prognostic
• Surrogate
• Validation
• Efficacy
• Predictive
• Other Biomarker Types

Services Covered:
• Assay Development
• Sample Preparation
• Testing
• Biomarkers
• Other Services

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Biomarkers Market, By Cancer Type
5.1 Introduction
5.2 Melanoma
5.3 Bladder Cancer
5.4 Breast Cancer
5.5 Kidney Cancer
5.6 Prostate Cancer
5.7 Lung Cancer
5.8 Non-Hodgkin's Lymphoma
5.9 Colorectal Cancer
5.10 Thyroid Cancer
5.11 Leukemia
5.12 Other Cancer Types

6 Global Cancer Biomarkers Market, By Product
6.1 Introduction
6.2 Software
6.3 Consumables
6.4 Growth Hormone Therapy
6.5 Services
6.6 Other Products

7 Global Cancer Biomarkers Market, By Profiling Technologies
7.1 Introduction
7.2 Immunoassay
7.3 Omics Technologies
7.4 Cytogenetics
7.5 Imaging Technologies
7.6 Bioinformatics
7.7 Other Profiling Technologies

8 Global Cancer Biomarkers Market, By Application
8.1 Introduction
8.2 Prognostics
8.3 Diagnostics
8.4 Risk Assessment
8.5 Research & Development
8.6 Hospitals & Specialty Clinics
8.7 Pharmaceutical & Biotechnology Companies
8.8 Other Applications

9 Global Cancer Biomarkers Market, By Biomarkers Type
9.1 Introduction
9.2 Genetic Biomarkers
9.3 Protein Biomarkers
9.4 Safety
9.5 Pharmacodynamics
9.6 Prognostic
9.7 Surrogate
9.8 Validation
9.9 Efficacy
9.10 Predictive
9.11 Other Biomarker Types

10 Global Cancer Biomarkers Market, By Service
10.1 Introduction
10.2 Assay Development
10.3 Sample Preparation
10.4 Testing
10.5 Biomarkers
10.6 Other Services

11 Global Cancer Biomarkers Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa

12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies

13 Company Profiling
13.1 Abbott Laboratories
13.2 Myriad Genetics, Inc.
13.3 F. Hoffmann-LA Roche Ltd.
13.4 Asuragen, Inc.
13.5 Biomérieux SA
13.6 Seegene Technologies, INC.
13.7 Thermo Fisher Scientific INC.
13.8 R&d Systems, Inc.
13.9 Becton Dickinson and Company
13.10 Qiagen N.V.
13.11 Hologic, Inc.
13.12 Illumina, Inc.
13.13 Bio-Rad Laboratories, INC.
13.14 Agilent Technologies
13.15 Merck Millipore

List of Tables
1 Global Cancer Biomarkers Market Outlook, By Region (2020-2028) ($MN)
2 Global Cancer Biomarkers Market Outlook, By Cancer Type (2020-2028) ($MN)
3 Global Cancer Biomarkers Market Outlook, By Melanoma (2020-2028) ($MN)
4 Global Cancer Biomarkers Market Outlook, By Bladder Cancer (2020-2028) ($MN)
5 Global Cancer Biomarkers Market Outlook, By Breast Cancer (2020-2028) ($MN)
6 Global Cancer Biomarkers Market Outlook, By Kidney Cancer (2020-2028) ($MN)
7 Global Cancer Biomarkers Market Outlook, By Prostate Cancer (2020-2028) ($MN)
8 Global Cancer Biomarkers Market Outlook, By Lung Cancer (2020-2028) ($MN)
9 Global Cancer Biomarkers Market Outlook, By Non-Hodgkin's Lymphoma (2020-2028) ($MN)
10 Global Cancer Biomarkers Market Outlook, By Colorectal Cancer (2020-2028) ($MN)
11 Global Cancer Biomarkers Market Outlook, By Thyroid Cancer (2020-2028) ($MN)
12 Global Cancer Biomarkers Market Outlook, By Leukemia (2020-2028) ($MN)
13 Global Cancer Biomarkers Market Outlook, By Other Cancer Types (2020-2028) ($MN)
14 Global Cancer Biomarkers Market Outlook, By Product (2020-2028) ($MN)
15 Global Cancer Biomarkers Market Outlook, By Software (2020-2028) ($MN)
16 Global Cancer Biomarkers Market Outlook, By Consumables (2020-2028) ($MN)
17 Global Cancer Biomarkers Market Outlook, By Growth Hormone Therapy (2020-2028) ($MN)
18 Global Cancer Biomarkers Market Outlook, By Services (2020-2028) ($MN)
19 Global Cancer Biomarkers Market Outlook, By Other Products (2020-2028) ($MN)
20 Global Cancer Biomarkers Market Outlook, By Profiling Technologies (2020-2028) ($MN)
21 Global Cancer Biomarkers Market Outlook, By Immunoassay (2020-2028) ($MN)
22 Global Cancer Biomarkers Market Outlook, By Omics Technologies (2020-2028) ($MN)
23 Global Cancer Biomarkers Market Outlook, By Cytogenetics (2020-2028) ($MN)
24 Global Cancer Biomarkers Market Outlook, By Imaging Technologies (2020-2028) ($MN)
25 Global Cancer Biomarkers Market Outlook, By Bioinformatics (2020-2028) ($MN)
26 Global Cancer Biomarkers Market Outlook, By Other Profiling Technologies (2020-2028) ($MN)
27 Global Cancer Biomarkers Market Outlook, By Application (2020-2028) ($MN)
28 Global Cancer Biomarkers Market Outlook, By Prognostics (2020-2028) ($MN)
29 Global Cancer Biomarkers Market Outlook, By Diagnostics (2020-2028) ($MN)
30 Global Cancer Biomarkers Market Outlook, By Risk Assessment (2020-2028) ($MN)
31 Global Cancer Biomarkers Market Outlook, By Research & Development (2020-2028) ($MN)
32 Global Cancer Biomarkers Market Outlook, By Hospitals & Specialty Clinics (2020-2028) ($MN)
33 Global Cancer Biomarkers Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
34 Global Cancer Biomarkers Market Outlook, By Other Applications (2020-2028) ($MN)
35 Global Cancer Biomarkers Market Outlook, By Biomarkers Type (2020-2028) ($MN)
36 Global Cancer Biomarkers Market Outlook, By Genetic Biomarkers (2020-2028) ($MN)
37 Global Cancer Biomarkers Market Outlook, By Protein Biomarkers (2020-2028) ($MN)
38 Global Cancer Biomarkers Market Outlook, By Safety (2020-2028) ($MN)
39 Global Cancer Biomarkers Market Outlook, By Pharmacodynamics (2020-2028) ($MN)
40 Global Cancer Biomarkers Market Outlook, By Prognostic (2020-2028) ($MN)
41 Global Cancer Biomarkers Market Outlook, By Surrogate (2020-2028) ($MN)
42 Global Cancer Biomarkers Market Outlook, By Validation (2020-2028) ($MN)
43 Global Cancer Biomarkers Market Outlook, By Efficacy (2020-2028) ($MN)
44 Global Cancer Biomarkers Market Outlook, By Predictive (2020-2028) ($MN)
45 Global Cancer Biomarkers Market Outlook, By Other Biomarker Types (2020-2028) ($MN)
46 Global Cancer Biomarkers Market Outlook, By Service (2020-2028) ($MN)
47 Global Cancer Biomarkers Market Outlook, By Assay Development (2020-2028) ($MN)
48 Global Cancer Biomarkers Market Outlook, By Sample Preparation (2020-2028) ($MN)
49 Global Cancer Biomarkers Market Outlook, By Testing (2020-2028) ($MN)
50 Global Cancer Biomarkers Market Outlook, By Biomarkers (2020-2028) ($MN)
51 Global Cancer Biomarkers Market Outlook, By Other Services (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

List of Figures


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.

Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.

For more details about research methodology, kindly write to us at

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.


Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.